Activist investor Elliott in talks with other GlaxoSmithKline investors about replacing Emma Walmsley, spinning off vaccine business — report
As Emma Walmsley reveals details this Wednesday about the upcoming split of GlaxoSmithKline’s pharma and consumer units, some tough questions may be coming her way.
Elliott Management, the activist investor that’s previously threatened an attack on GSK (but eventually backed off), is floating more radical changes like replacing the CEO, further breaking up the company and spinning out the vaccine unit, or reviewing the focus on cancer drugs, the Financial Times reported.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.